+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.

Age: 18Years - 75YearsAll GendersPhase 2
87 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.

Age: 18Years - 55YearsAll GendersPhase 2
101 locations
C

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the effectiveness of a character-strengths based coaching program designed to reduce work-related stress and improve mental wellbeing among Accredited Social Health Activists ASHAs, who are rural female health workers in India. The study compares this coaching intervention to routine health worker supervision, focusing on self-reported wellbeing measured by the Authentic Happiness Inventory at three months. The trial also assesses other wellbeing indicators such as affect, self-efficacy, flourishing, burnout, and motivation, as well as service delivery and patient outcomes related to depression care. Participants are randomly assigned to one of two groups the intervention group receives a five-day residential workshop focused on character strengths and strategies to manage work stress, followed by 8 to 10 weeks of weekly telephonic coaching sessions. The control group continues with the usual weekly face-to-face supervision provided by their supervisors in group settings. The coaching sessions are individually delivered by assigned coaches via phone and last about 30 to 45 minutes each. During the study, participants will complete assessments at baseline, one month, three months, and six months to measure wellbeing and related factors. Data collection includes self-reported questionnaires on happiness, affect, burnout, and motivation. Researchers will also explore the impact of the intervention on work performance and patient satisfaction. Outcomes will be collected by assessors unaware of group assignments to ensure unbiased results. The total participation period includes multiple follow-ups to monitor both short- and medium-term effects.

Age: 18Years +FEMALEPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are evaluating whether a deprescribing tool can help reduce prescriptions with potentially inappropriate medications PIMs among elderly patients in India. The study aims to determine if inappropriate polypharmacy can be lowered by developing and implementing a tool tailored to the Indian context, where medication use patterns differ from other countries. This trial compares outcomes between physicians who use the deprescribing tool and those who follow routine prescribing practices. In this multicenter study, physicians are randomly assigned to either a control group that prescribes as usual or an intervention group that uses the deprescribing tool during patient consultations. The tool guides medication review and deprescribing decisions, such as stopping duplicate drugs, tapering unnecessary medications, or reducing doses. Patients aged 60 years and older receive routine care from their assigned physician, and prescriptions are collected for evaluation. Participants are followed for one month after the consultation to monitor adverse events, including hospitalizations. Data collected include the proportion of prescriptions containing PIMs, average number of PIMs per prescription, deprescribing rates, and potential adverse drug reactions or interactions. Researchers assess the impact of the tool on improving prescription quality and reducing medication-related risks, with the total participation lasting from enrollment through follow-up.

Age: 60Years +All GendersPhase Not Applicable
2 locations
E

Actively Recruiting

This research aims to evaluate a culturally tailored mobile interactive education and support group intervention called MeSSSSage among postpartum Indian women. The study focuses on improving health-related knowledge, behaviors, and outcomes for mothers and newborns, addressing challenges like limited postpartum care access and social isolation. It is a randomized controlled trial involving 2100 women from three diverse Indian states, intending to assess the interventions impact, mechanisms, and cost-effectiveness. Participants in the intervention group receive 26 education and support sessions over eight months, including two prenatal and weekly postpartum sessions up to six months after birth. The sessions are delivered via audioconference and moderated by community health workers, with additional engagement through a provider-moderated group text chat. The control group receives standard postnatal care. The intervention is designed to supplement usual care and overcome barriers through mobile technology and social support. During the study, participants will be assessed on exclusive breastfeeding, postpartum depression, and family planning adoption at six months. Other outcomes include knowledge of maternal and neonatal danger signs, healthcare use, and infant vaccination. Researchers will monitor participant engagement and analyze how the intervention influences knowledge, social support, self-efficacy, and behaviors. The study also includes cost-effectiveness analyses and will follow participants for eight months to gather comprehensive data on postpartum health and well-being.

Age: 18Years - 49YearsFEMALEPhase Not Applicable
3 locations